Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Nivolumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Biopsy 2trastuzumab deruxtecan 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Taxes 1Sigmoidoscopy 1Radionuclide Imaging 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin 1Magnetic Resonance Imaging 1Ipilimumab 1Ibuprofen 1Epinephrine 1Electrocardiography 1Diphenhydramine 1Dexamethasone 1Colonoscopy 1Carboplatin 1Calcium Dobesilate 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anus Neoplasms × Proctoscopy × 30 days × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡